These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 31200447)

  • 1. Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases.
    Pellegrini C; Fornai M; Antonioli L; Blandizzi C; Calderone V
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31200447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases.
    Jahan S; Kumar D; Chaturvedi S; Rashid M; Wahajuddin M; Khan YA; Goyal SN; Patil CR; Mohanraj R; Subramanya S; Ojha S
    Curr Med Chem; 2017; 24(16):1645-1670. PubMed ID: 28245768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phytochemical inhibitors of the NLRP3 inflammasome for the treatment of inflammatory diseases.
    Özenver N; Efferth T
    Pharmacol Res; 2021 Aug; 170():105710. PubMed ID: 34089866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory Role of Berberine, an Isoquinoline Alkaloid, on NLRP3 Inflammasome Activation for the Treatment of Inflammatory Diseases.
    Sarbadhikary P; George BP; Abrahamse H
    Molecules; 2021 Oct; 26(20):. PubMed ID: 34684819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the NLRP3 Inflammasome in Neuroinflammation: Health Promoting Effects of Dietary Phytochemicals in Neurological Disorders.
    Hung WL; Ho CT; Pan MH
    Mol Nutr Food Res; 2020 Feb; 64(4):e1900550. PubMed ID: 31675164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders.
    Wang Z; Hu W; Lu C; Ma Z; Jiang S; Gu C; Acuña-Castroviejo D; Yang Y
    Arterioscler Thromb Vasc Biol; 2018 Dec; 38(12):2765-2779. PubMed ID: 30571177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?
    Pellegrini C; Antonioli L; Calderone V; Colucci R; Fornai M; Blandizzi C
    Prog Neurobiol; 2020 Aug; 191():101806. PubMed ID: 32473843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of phytochemicals on NLRP3 inflammasome activation: A review.
    Olcum M; Tastan B; Ercan I; Eltutan IB; Genc S
    Phytomedicine; 2020 Aug; 75():153238. PubMed ID: 32507349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors.
    Zhao N; Li CC; Di B; Xu LL
    J Autoimmun; 2020 Sep; 113():102515. PubMed ID: 32703754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NLRP3 Inflammasome as a Pharmacological Target.
    Marchetti C
    J Cardiovasc Pharmacol; 2019 Oct; 74(4):285-296. PubMed ID: 31335445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Inhibitory Capacities of 6-, 8- and 10-Gingerols/Shogaols on the Canonical NLRP3 Inflammasome-Mediated IL-1β Secretion.
    Ho SC; Chang YH
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29466287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinones as preventive agents in Alzheimer's diseases: focus on NLRP3 inflammasomes.
    Chen DB; Gao HW; Peng C; Pei SQ; Dai AR; Yu XT; Zhou P; Wang Y; Cai B
    J Pharm Pharmacol; 2020 Nov; 72(11):1481-1490. PubMed ID: 32667050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial Properties of Phytochemicals on NLRP3 Inflammasome-Mediated Gout and Complication.
    Jhang JJ; Lin JH; Yen GC
    J Agric Food Chem; 2018 Jan; 66(4):765-772. PubMed ID: 29293001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on the Role of NLRP3 Inflammasome in Diseases.
    Fusco R; Siracusa R; Genovese T; Cuzzocrea S; Di Paola R
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation.
    Pellegrini C; Antonioli L; Lopez-Castejon G; Blandizzi C; Fornai M
    Front Immunol; 2017; 8():36. PubMed ID: 28179906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications.
    Pellegrini C; Martelli A; Antonioli L; Fornai M; Blandizzi C; Calderone V
    Med Res Rev; 2021 Jul; 41(4):1890-1926. PubMed ID: 33460162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRP3 inflammasome in ischemic stroke: As possible therapeutic target.
    Alishahi M; Farzaneh M; Ghaedrahmati F; Nejabatdoust A; Sarkaki A; Khoshnam SE
    Int J Stroke; 2019 Aug; 14(6):574-591. PubMed ID: 30940045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NLRP3 inflammasome: Role in metabolic disorders and regulation by metabolic pathways.
    Jiang D; Chen S; Sun R; Zhang X; Wang D
    Cancer Lett; 2018 Apr; 419():8-19. PubMed ID: 29339210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NLRP3 Inflammasome: An Emerging Therapeutic Target for Alzheimer's Disease.
    Tao S; Fan W; Liu J; Wang T; Zheng H; Qi G; Chen Y; Zhang H; Guo Z; Zhou F
    J Alzheimers Dis; 2023; 96(4):1383-1398. PubMed ID: 37980662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Impact of Bioactive Compounds as NLRP3 Inflammasome Inhibitors: An Update.
    Singh S; Sharma S; Sharma H
    Curr Pharm Biotechnol; 2024; 25(13):1719-1746. PubMed ID: 38173061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.